Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase by Fujihashi, Toshiaki et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Biochemistry and Molecular Biology
Faculty Papers Department of Biochemistry and Molecular Biology
September 1995
Anti-human immunodeficiency virus (HIV)
activities of halogenated gomisin J derivatives, new
nonnucleoside inhibitors of HIV type 1 reverse
transcriptase
Toshiaki Fujihashi
Thomas Jefferson University
Hiroto Hara
University of Pennsylvania
Toshiya Sakata
Thomas Jefferson University
Kazuya Mori
Institute for Molecular Genetics, Japan
Hirotaka Higuchi
University of Pennsylvania
See next page for additional authorsLet us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/bmpfp
Part of the Medical Biochemistry Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Biochemistry and Molecular Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Fujihashi, Toshiaki; Hara, Hiroto; Sakata, Toshiya; Mori, Kazuya; Higuchi, Hirotaka; Tanaka, Akio;
Kaji, Hideko; and Kaji, Akira, "Anti-human immunodeficiency virus (HIV) activities of halogenated
gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase" (1995).
Department of Biochemistry and Molecular Biology Faculty Papers. Paper 15.
http://jdc.jefferson.edu/bmpfp/15
Authors
Toshiaki Fujihashi, Hiroto Hara, Toshiya Sakata, Kazuya Mori, Hirotaka Higuchi, Akio Tanaka, Hideko Kaji,
and Akira Kaji
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/bmpfp/15
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1995, p. 2000–2007 Vol. 39, No. 9
0066-4804/95/$04.0010
Copyright q 1995, American Society for Microbiology
Anti-Human Immunodeficiency Virus (HIV) Activities of Halogenated
Gomisin J Derivatives, New Nonnucleoside Inhibitors
of HIV Type 1 Reverse Transcriptase
TOSHIAKI FUJIHASHI,1† HIROTO HARA,2 TOSHIYA SAKATA,1† KAZUYA MORI,3†
HIROTAKA HIGUCHI,2† AKIO TANAKA,2 HIDEKO KAJI,1 AND AKIRA KAJI2*
Department of Pharmacology, Jefferson Medical College, Philadelphia, Pennsylvania 191071; Institute for Molecular Genetics,
Tsumura and Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki, 300-11 Japan3; and Department of
Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-60762
Received 22 February 1995/Returned for modification 3 April 1995/Accepted 6 July 1995
Halogenated gomisin J (a derivative of lignan compound), represented by the bromine derivative 1506 {(6R, 7S,
S-biar)-4,9-dibromo-3,10-dihydroxy-1,2,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c]cyclo-
octene}, was found to be a potent inhibitor of the cytopathic effects of human immunodeficiency virus type 1(HIV-1)
on MT-4 human T cells (50% effective dose, 0.1 to 0.5 mM). Gomisin J derivatives were active in preventing p24
production from acutely HIV-1-infected H9 cells. The selective indices (toxic dose/effective dose) of these com-
pounds were as high as >300 in some systems. 1506 was active against 3*-azido-3*-deoxythymidine-resistant
HIV-1 and acted synergistically with AZT and 2*,3*-ddC. 1506 inhibited HIV-1 reverse transcriptase (RT) in
vitro but not HIV-1 protease. From the time-of-addition experiment, 1506 was found to inhibit the early phase
of the HIV life cycle. A 1506-resistant HIV mutant was selected and shown to possess a mutation within the
RT-coding region (at position 188 [Tyr to Leu]). The mutant RT expressed in Escherichia coli was resistant to
1506 in the in vitro RT assay. Some of the HIV strains resistant to other nonnucleoside HIV-1 RT inhibitors
were also resistant to 1506. Comparison of various gomisin J derivatives with gomisin J showed that iodine,
bromine, and chlorine in the fourth and ninth positions increased RT inhibitory activity as well as cytopro-
tective activity.
Lignans are phenylpropanoid dimers distributed very widely
in the plant kingdom. There are various kinds of lignan de-
pending on the mode of dimerization of phenylpropanoid.
Gomisin is a dibenzocyclooctadiene-type lignan compound
and a component of Schizandra fruit extracts (30–32, 70).
There are various types of gomisins, A, B, C, D, E, F, G, J, and
N; some possess central nervous system depressant, analgesic,
antitussive, and/or Ca antagonist activities (42, 69). As for the
antiviral activities of lignans, it has been reported that tetra-
hydronaphthalene-type lignans have selective inhibitory activ-
ities on herpes simplex virus and cytomegalovirus (41, 43) and
that dibenzylbutanolide-type lignans have an inhibitory effect
on human immunodeficiency virus (HIV) replication (63).
However, the ratio of toxic dose to effective dose (selective
index) of dibenzylbutanolide-type lignan was no more than 5,
suggesting that this could not be used as a clinically effective
anti-HIV agent.
In continuation of our search for anti-HIV agents (19, 20,
26, 52), we report in this paper new gomisin J derivatives which
have potent anti-HIV activities with much higher selective
indices than that of dibenzylbutanolide-type lignan. The high-
est selective index among gomisin J derivatives was over 300.
MATERIALS AND METHODS
Chemicals. Gomisin J was isolated as previously described (32). Halogenated
derivatives (Fig. 1) of gomisin J were synthesized from gomisin J by using
halogenizing agents such as N-bromosuccinimide. Detailed descriptions of syn-
thesis and characterization will be published elsewhere. Structures of pure, newly
synthesized compounds were determined by nuclear magnetic resonance and
infrared analyses. These compounds were kindly provided by Tanaka, Tsumura
Central Research Institute, Ibaraki, Japan. 39-Azido-39-deoxythymidine (AZT)
and 29,39-ddC were purchased from Sigma Chemical Co. (St. Louis, Mo.). Tet-
rahydroimidazo[4,5,1-jk] [1,4]-benzodiazepin-2(1H)-one (TIBO) derivative
R82150 (53) and HIV protease (PR) inhibitor Ro 31-8959 (9) were kindly
provided by M. Janssen (Janssen, Beerse, Belgium) and N. A. Roberts (Roche
Products Limited, Herts, United Kingdom), respectively. All gomisin J deriva-
tives were dissolved in dimethyl sulfoxide. The final concentration of dimethyl
sulfoxide in culture medium was adjusted to 0.3%. AZT and ddC were dissolved
in water.
Cells and viruses. Human T-cell line MT-4 cells (25), Sup-T1 cells (67), and
H9 cells (56) were kindly provided by N. Yamamoto (Tokyo Medical and Dental
University, Tokyo, Japan), J. A. Hoxie (University of Pennsylvania, Philadelphia,
Pa.), and H. Mitsuya (National Cancer Institute, Bethesda, Md.), respectively.
Chronically HIV type 1 (HIV-1)-infected H9 cells (H9/IIIB) and MT-2 cells (25)
were provided by the National Institutes of Health AIDS Research and Refer-
ence Reagent Program. Chronically HIV-1-infected Molt-4 cells (Molt-4/HTLV-
IIIB) were kindly provided by E. Henderson (Temple University, Philadelphia,
Pa.). These cells were grown in 25 mM HEPES (N-hydroxyethylpiperazine-N9-
2-ethanesulfonic acid)-buffered RPMI 1640 (GIBCO) supplemented with 10%
fetal calf serum, 100 U of penicillin per ml, 100 mg of streptomycin per ml, and
0.25 mg of amphotericin B per ml. At this concentration, amphotericin B is
effective as an antimycotic in tissue culture but has no inhibitory activity for HIV
replication (50, 64). HIV-1 was prepared from a culture supernatant of Molt-4/
HTLV-IIIB cells. The post-AZT isolates (A012D) of HIV-1 (38), simian immu-
nodeficiency virus (SIV) MAC251 (10), A17 variant strain of HIVIIIB resistant to
pyridinone (51), and N119 nevirapine-resistant HIV-1 (61) were provided by the
National Institutes of Health AIDS Research and Reference Reagent Program.
A TIBO-resistant strain of HIV-1, L100I (46), was kindly supplied by J. W.
Mellors (University of Pittsburgh Medical Center, Pittsburgh, Pa.).
Anti-HIV-1 assays of cultured cell lines. The procedure for measuring the
cytoprotective activities of samples with MT-4 cells has previously been described
(54) and was performed with slight modifications as described previously (20).
The anti-HIV activity of the compound was expressed as the concentration
required to reduce the number of dead cells to 50% of the control without an
anti-HIV agent (ED50). The cytotoxic effect on uninfected MT-4 cells was as-
sessed by incubating uninfected cells with the compound under the same condi-
tions as described above, except for the HIV addition, and expressed as the
concentration required to kill 50% of cells (CD50). Anti-HIV-1 activity with
Sup-T1 cells was determined by counting the total number of multinuclear giant
* Corresponding author.
† Present address: New Drug Discovery Laboratories, Tsumura and
Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki, 300-11 Japan.
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cells in each well 4 days after viral infection (1, 52). The cytotoxic effect against
uninfected Sup-T1 cells was assessed by incubating uninfected cells with the
compound for 7 days. The procedure for measuring viral p24 production by
infected H9 cells was previously described (5, 20, 52). Cell number was deter-
mined by the MTT method (49).
Syncytium inhibition assay. The syncytium assay was performed on a 96-well
microplate by mixing 5 3 104 Sup-T1 cells with 2.5 3 104 H9/IIIB cells at 378C
in a CO2 incubator for 18 h (44). The test compound was present in the medium
throughout the test. The number of giant cells in each well was counted by
microscopic examination.
Viral p24 expression in chronically HIV-1-infected cells. To study the inhibi-
tion of HIV-1 production by 1506 in chronically infected cells, 5 3 104 H9/IIIB
cells were incubated for 5 days in the presence of test compounds. The amount
of viral p24 in supernatant fluid on the fifth day of culture was determined. The
cytotoxicities of test compounds for H9/IIIB cells were determined by the MTT
method on day 5 after the addition of test compounds.
HIV-1 RT and PR assays. The inhibitory effects of 1506 on wild-type reverse
transcriptase (RT) and mutant RT with an amino acid change at the 188th
position (T-1883L [T188L]) were studied by using plasmids harboring either the
wild-type or mutated RT gene kindly supplied by S. H. Hughes (National Cancer
Institute). Escherichia coli DH5a was transformed with plasmids containing one
of these genes, and crude RTs were prepared as previously described (4, 27).
HIV-1 RT assays were performed as previously described (52, 71).
For HIV-1 PR assays (59), purified HIV-1 PR (2.5 mg/ml; Bachem) and 28
mM synthetic peptide (HIV substrate III; Bachem) [His-Lys-Ala-Arg-Val-Leu-
(p-NO2)Phe-Glu-Ala-Nle-Ser-amide] were incubated with various concentra-
tions of test compound in 40 ml of reaction buffer (100 mM NaOAc [pH 5.5], 1.6
M NaCl, 1.2 mM dithiothreitol) for 3 h at 378C. Reactions were terminated by
the addition of an equal volume of 10% AcOH. The cleavage product was
quantitated by high-pressure liquid chromatography with a YMC-AM312 col-
umn. The inhibitory effect of each test compound was expressed as the concen-
tration required to reduce enzyme activity by 50% (IC50).
Drug combination. The combined effects of 1506 and AZT or ddC were
examined with MT-4 cells infected with HIV-1IIIB under the experimental con-
ditions used for the determination of ED50. To assess whether the drug combi-
nation resulted in synergistic, additive, or antagonistic effects, the isobologram
technique was used (17, 60).
Time-of-addition experiment. To determine the target step of 1506 in the HIV
life cycle, the time-of-addition experiment was performed according to the
method previously described (14).
Isolation of 1506-resistant HIV-1 variants. The selection of HIV-1 variants
resistant to 1506 was performed essentially as previously described for other
resistant HIV mutants (21, 22). MT-4 cells (5 3 105 cells per ml) were infected
with HIVIIIB in the presence of subeffective concentrations of drugs. The amount
of 1506 was gradually increased during subsequent passages. For each passage,
cultures were infected with the HIV obtained from the preceding passage. The
resistant mutant thus obtained was named 1506R.
Identification of the nucleotide change causing resistance to 1506.MT-4 cells
(107 cells) infected with wild-type HIV-1 or 1506R were cultured for 2 days. Cells
were pelleted, and cellular DNA with integrated HIV-1 DNA was prepared by
using the Qiagen genomic DNA preparation kit. A portion (0.5 mg) of cellular
DNA was subjected to PCR with 21-mer primers (1 and 2 primers correspond-
ing to positions 1869 through 1889 and 3974 through 3994 [58] of HIVhxb2 [55,
57, 65], respectively). PCR was performed with Vent polymerase (35 cycles)
(Perkin-Elmer Cetus). The 2.1-kb PCR product was electrophoretically eluted
after separation by gel electrophoresis and was used for the second PCR (25
cycles). The amplified 2.1-kb PCR products were subjected to DNA sequencing
without subcloning (Cycle DNA Sequencing; Bethesda Research Laboratories).
Sequence analysis was repeated on DNA prepared from an independent PCR,
and the results were identical.
Southern blot analysis of HIV-1 DNA. H9 cells were infected with HIV-1IIIB
and cultured in the presence or absence of 1506 (7.4 mM [nontoxic dose]) for 24
h (34). DNA was prepared from 24-h-cultured cells by using the Qiagen genomic
DNA preparation kit. Each undigested DNA sample (5 mg) was subjected to
agarose gel electrophoresis, with subsequent Southern blotting analysis. The
blotted filter was probed with 32P-labeled HIV-1 genomic DNA (9.4-kb BstEI-
BstEI fragment), prepared from l DNA harboring HIVhxb2 (55, 57, 65) which
was provided by the National Institutes of Health AIDS Research and Reference
Reagent Program.
RESULTS
Antiretroviral activities of gomisin J derivatives in MT-4
cells. In the course of screening over 400 compounds of plant
origin, we found that a lignan derivative, (2)-gomisin J, iso-
lated from Schizandra chinensis BAILL had significant anti-
HIV activity. Other lignan components [such as gomisins A, D,
E, and N, deoxyshizandrin, and (1)-gomisin J] failed to exhibit
anti-HIV action (data not shown). Among the various gomisin
J derivatives tested for anti-HIV-1 activities in the MT-4 cell
system, 4,9-dihalogenated gomisin J derivatives were found to
be potent inhibitors (ED50s of 0.39 to 1.23 mM) of HIV-1-
induced cytopathicity (Table 1). The anti-HIV-1 activity of
1506 {(6R, 7S, S-biar)-4,9-dibromo-3,10-dihydroxy-1,2,11,12-
tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c]cy-
clooctene} was 33-fold stronger than that of (2)-gomisin J.
Other derivatives, 1580 (iodine in place of bromine) and 1689
(chlorine in place of bromine), were also effective.
The gomisin J derivatives were similar to other known non-
nucleoside HIV RT inhibitors in that they were specific inhib-
itors of HIV-1 and did not inhibit HIV-2 or SIV replication
(Table 2). In contrast, AZT was effective against all of these
viruses, confirming previous reports (23, 35, 45, 47, 53).
Inhibition of HIV-1-induced giant cell formation and p24
production by gomisin J derivatives. Gomisin J derivatives
were effective in tests of their protective effects on giant cell
formation induced by HIV-1 infection of an HIV-infected hu-
FIG. 1. Chemical structures of gomisin J and related compounds.
TABLE 1. Anti-HIV-1 activities of gomisin J and related
compounds in culture cellsa
Compound Assay systemb ED50 (mM) CD50 (mM)
Selective
indexc
(2)-Gomisin J Cell death 17.5 90.9 5.2
1689 Cell death 1.23 6 0.20 41.9 6 11.1 34.1
1506 Cell death 0.52 6 0.06 21.1 6 1.5 40.6
1580 Cell death 0.39 6 0.05 21.0 6 4.8 53.8
1689 Giant cell formation 1.52 6 0.51 31.3 6 3.2 20.6
1506 Giant cell formation 0.39 6 0.09 14.9 6 1.6 38.2
1580 Giant cell formation 0.16 6 0.04 17.5 6 4.2 109.4
1689 p24 production 0.68 6 0.25 28.5 6 3.5 41.9
1506 p24 production 0.13 6 0.03 24.0 6 3.6 184.6
1580 p24 production 0.06 6 0.01 22.5 6 5.3 375.0
a Cells were infected with 50 HIV units per well (63 104 cells per well) for cell
death, 500 HIV units per well (5 3 104 cells per well) for giant cell formation,
and 80 HIV units per well (4 3 104 cells per well) for p24 production assays.
Antiviral effective dose required to achieve 50% inhibition of HIV infection was
measured. One HIV unit was defined as the amount of virus that killed 50% of
infected MT-4 cells within 5 days of infection. Data are the means and standard
errors of three or more determinations, except for the (2)-gomisin J data, which
are the means of duplicate determinations.
bMT-4, Sup-T1, and H9 cells were used in cell death, giant cell formation, and
p24 production assays, respectively.
c Ratio of CD50 to ED50.
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man T-cell line (Sup-T1) (Table 1). 1580 was the most potent
compound for inhibiting giant cell formation among the three
halogenated gomisin J derivatives, followed by 1506 and 1689.
The iodine derivative (1580) of gomisin J gave the highest
selective index (CD50/ED50). The gomisin J derivatives were
shown to be effective in reducing p24 production in acutely
infected H9 cells (Table 1). The IC50s of these gomisin J
derivatives for p24 production in this cell system were lower
than those for the MT-4 and Sup-T1 cell systems. The iodine
derivative (1580) was the most active, followed by the bromine
(1506) and chlorine (1689) derivatives.
Lack of inhibitory effect on CD4-gp120 interaction and HIV
production from chronically HIV-infected cells. When chron-
ically infected H9 cells (H9/IIIB) and Sup-T1 cells are mixed,
the CD4 receptor on Sup-T1 cells and HIV-1 gp120 on the
membrane of H9/IIIB cells interact with each other, resulting
in syncytium formation (68). No gomisin J derivative inhibited
this system (data not shown). Tested under the same condi-
tions, dextran sulfate (molecular weight, 8,000) inhibited syn-
cytium formation by 50% at a concentration of 4.4 mM (2).
To investigate whether gomisin J derivatives inhibit the late
stage of the HIV life cycle, we tested the effects of 1506 on p24
production by chronically infected H9 cells. Compound 1506
failed to reduce p24 production in this system at the dose
which does not influence cell viability (data not shown). The
positive control, PR inhibitor Ro 31-8959 (9), inhibited p24
production.
Time-of-addition experiment. Inhibitors were added at var-
ious times after HIV infection. Inhibitors, such as dextran
sulfate, that act at the early step (2) must be added early to be
effective, while those that act at the late step, such as HIV PR
inhibitors (9), can be added later. As shown in Fig. 2, AZT,
which acts at the RT step (48), was added to cells up to 6 h
after infection without any loss of activity. The activity time
courses of compounds 1506 and 1580 were comparable to that
of AZT.
Effects of gomisin J derivatives on HIV-1 RT and HIV-1 PR
activities. Although 1506 inhibited HIV-1 RT with poly(rA) z
oligo(dT)12–18, the IC50 of 1506 for RT activity was 6- to
26-fold higher than the ED50 for anti-HIV action (data not
shown). Inhibitory activities were about 2-fold higher with
poly(rC) z oligo(dG)12–18, but the ED50s of these anti-HIV
agents were still lower than the IC50s for HIV RT. The IC50s
of (2)-gomisin J, 1689, 1506, and 1580 were 45.0, 1.2, 1.1, and
0.8 mM, respectively. [These data are the means of two deter-
minations, with poly(rC) z oligo(dG)12–18 (1:1 mixture by
weight) as the primer-template.] Although the exact correla-
tion between the cytoprotective and RT inhibitory activities of
halogenated derivatives was not obtained, 1580 was the most
potent agent in both of these assays. The data show that the
halogenation of gomisin J increased anti-HIV activity through
its increase in the inhibitory activity of RT. Compound 1506
did not inhibit HIV-1 PR, even at a concentration that was
over 300-fold the effective concentration in this cell culture
system (data not shown).
Kinetic studies with HIV-1 RT. Although 1580 (the iodine
derivative) proved to be the most effective, it was found to be
chemically more labile than the bromine derivative (1506).
For this reason, most of the subsequent detailed studies
were carried out with 1506 as the representative of haloge-
nated gomisin J derivatives. Kinetic studies were performed
with purified recombinant HIV-1 RT and various substrate
(dGTP) and template-primer [poly(C) z oligo(dG)] concen-
trations. As shown in Fig. 3, the inhibition of RT by 1506
appeared to be noncompetitive with regard to the substrate
and mixed (noncompetitive and uncompetitive) with respect to
the template-primer. This contrasts with repandusinic acid, a
nonnucleoside RT inhibitor, which gives competitive inhibition
with respect to the primer-template of HIV RT (52). From the
data presented in Fig. 3 and the Dixon plot of these data (15),
the Km for dGTP and Ki for 1506 were calculated to be 1.5 and
2.2 mM (at the template-primer complex concentration of 5
mg/ml), respectively. On the other hand, the Km for the tem-
plate-primer complex was 1.5 mg/ml (1 mg contains 0.5 mg of
primer and 0.5 mg of template), whereas the Ki for 1506 varied
slightly, depending on the template-primer concentration
(from 2.2 mM at 5 mg of template-primer per ml to 3.2 mM at
1 mg of template-primer per ml), in a manner similar to the Ki
of TIBO (12).
HIV-1 mutant resistant to 1506. After 20 passages of HIV-
1IIIB in MT-4 cells in the presence of 1506, a virus strain,
1506R, for which the ED50 of 1506 was higher than 10 mM was
obtained. We found no difference in nucleotide sequence be-
tween wild-type HIV-1 and 1506R in the integrase-coding re-
gion (data not shown). On the other hand, four nucleotide
changes were detected in the RT-coding region. Two changes
at nucleotides 2691 (T to C) and 2692 (A to T) resulted in a
substitution at amino acid 188 from Tyr to Leu. The other
changes at nucleotides 2718 (G to A) and 2745 (G to A),
corresponding to amino acids 196 (Gly) and 205 (Leu), re-
sulted in no amino acid substitutions. These results confirmed
the notion that the target step of gomisin J is the RT step of
HIV.
FIG. 2. Time-of-addition experiment. H9 cells were infected with HIV-1IIIB
at a multiplicity of infection of 0.1, and compounds were added at various times
postinfection (p.i.) as described in Materials and Methods. The amounts of p24
accumulated at 29 h p.i. were determined with a Coulter enzyme assay kit. E, no
drug; F, 1506 (7.4 mM); n, 1580 (7 mM); , AZT (1.9 mM);h, Ro 31-8959 (HIV
PR inhibitor; 0.65 mM); 3, dextran sulfate (molecular weight, 8,000; 6.3 mM).
TABLE 2. Lack of activities of gomisin J derivatives against
HIV-2 and SIV in MT-4 target cells
Virus Strain
ED (mM)a
1506 1689 1580 R82150 AZT
HIV-2 ROD .18 .22 .16 .105 0.106
HIV-2 CBL-20 .18 .22 .16 .105 0.024
SIV MAC251 18 (ED30) 22 (ED8) 16 (ED37) .105 0.010
a Data are ED50s unless noted otherwise.
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Activities of gomisin J derivatives against various drug-
resistant strains of HIV-1. In the experiments whose results
are shown in Table 3, the effects of gomisin J derivatives on
various HIV-1 strains with RTs which are resistant to various
anti-HIV agents were studied. The HIV-1 mutants tested were
L100I (resistant to TIBO) (46), N119 (resistant to nevirapine)
(61), A17 (resistant to pyridinone) (51), and A012D (resistant
to AZT) (38). All three compounds, 1506, 1689, and 1580,
behaved identically toward the various HIV-1 mutants, sug-
gesting that variations in halogen at the fourth and ninth po-
sitions of gomisin J do not change the basic mechanism of this
action. Moreover, gomisin J derivatives did not exert any ap-
preciable effect on mutants resistant to nevirapine, thus sug-
gesting that the mode of action of our compounds is similar to
that of nevirapine. In addition, gomisin J derivatives were
effective against mutants resistant to AZT or TIBO. This is
consistent with the fact that 1506R was sensitive to AZT. On
the other hand, 1506R was resistant to TIBO. Mutants 1506R,
N119 (nevirapine resistance), and A17 (pyridinone resistance)
possess increased resistance to all other nonnucleoside inhib-
itors, although the degree of resistance varies depending on
the mutant.
In vitro evidence that the RT of 1506R is resistant to 1506.
To confirm that the mutational change at the 188th position in
the RT-coding region identified in 1506R confers on the mu-
tated RT resistance to 1506, we compared the inhibitory effects
of 1506 on crude preparations of wild-type and mutated RTs.
As shown in Fig. 4, 20 mM 1506 inhibited wild-type RT by
about 50%, whereas the mutated RT was not inhibited at all,
even at a concentration of 100 mM. In confirmation of the
resistance of 1506R to TIBO (R82150) (Table 3), the mutant
RT was not inhibited by 40 mM TIBO, while wild-type RT was
inhibited by 50% by 0.03 mM TIBO. As noted in this figure, a
somewhat higher concentration of 1506 was required to inhibit
the crude RT prepared from E. coli. This was perhaps due to
interference by bacterial components. Nevertheless, the assay
was valid because the mutated and wild-type enzymes were
equally sensitive to foscarnet, a completely different RT inhib-
itor.
1506 acts synergistically with AZT. The results presented
above (Table 3) showed that the mode of action of 1506 was
different from those of nucleoside analogs such as AZT, sug-
gesting that combinations of 1506 and nucleoside inhibitors
may result in synergistic effects. In Fig. 5, the protection of
MT-4 cells by 1506 alone was compared with that by a combi-
nation of 1506 and nucleoside inhibitors. Compound 1506
acted synergistically with nucleoside inhibitors.
FIG. 3. Double-reciprocal plot analysis of purified recombinant HIV-1 RT
inhibition by 1506. Reactions were performed in 50 ml containing various con-
centrations of dGTP (a) or poly(C) z oligo (dG) (b) and 1506 at 0 (E), 0.1 (F),
0.2 (), 0.5 (h), or 1 (n) mM. Five micrograms of poly(C) z oligo(dG) per ml (a)
and 10 mM dGTP (b) were also present.
TABLE 3. Activities of gomisin J derivatives against various drug-resistant HIV-1 strains
Strain RT mutation(s) Targetcell
ED (mM)a
1506 1689 1580 R82150 Nevirapine AZT
IIIB None MT-4 0.63 6 0.20 1.42 6 0.49 0.26 6 0.05 0.18 6 0.05 0.17 6 0.03 0.05 6 0.03
L100Ib L100I MT-4 1.25 6 0.05 1.42 6 0.17 0.66 6 0.20 47.2 6 10.2 0.71 6 0.35 0.01 6 0.005
N119c Y181C MT-2 .20 .20 .20 69.3 6 33.0 .100 0.12 6 0.06
A17d K103N, Y181C MT-4 20 (ED30) 20 (ED20) 8.71 6 1.80 .100 100 (ED25) 0.02 6 0.004
1506Re Y188L MT-4 .20 .20 .20 .100 .100 0.07 6 0.03
A012Df D67N, K70R, T215F, K219Q MT-2 2.19 4.38 0.81 ND ND .100
a Data are ED50s unless noted otherwise and are the means and standard errors of three determinations. ND, not determined.
b Selected in the presence of TIBO (R82150) (46).
c Selected in the presence of BI-RG-587 (nevirapine) (61).
d Selected in the presence of pyridinone RT inhibitor (51).
e Selected in the presence of 1506.
f Isolated after AZT treatment (resistant to AZT) (38).
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Detection of HIV-1 linear DNA after HIV-1 infection. To
further establish that 1506 inhibits HIV-1 RT, the presence of
linear HIV-1 DNA in infected cells was examined by Southern
blotting (data not shown). Viral linear DNA was detected in
control HIV-1-infected cells and cells treated with a PR inhib-
itor (Ro 31-8959). In contrast, AZT and 1506 reduced the
amount of HIV-1 DNA to an undetectable level. The viability
of drug-treated cells under these conditions was comparable to
that of control cells on day 1 (at the time of DNA preparation)
and day 4 (at the time when the cytoprotective effect was
confirmed). These results indicate that 1506 interferes with the
RT step in HIV-1-infected cells (just as AZT does).
DISCUSSION
In our continued attempts to develop an effective anti-HIV
agent (19, 20, 26, 52), we found that 4,9-halogenated gomisin J
derivatives have potent anti-HIV activities with high selective
indices (some of them are over 300). We conclude that these
derivatives exert their anti-HIV activities through their inhib-
itory effects on HIV-1 RT. The mode of action of these gomi-
sin J derivatives is completely different from that of other
anti-HIV lignan derivatives, which have been reported to in-
hibit topoisomerase II (63).
Though nonnucleoside HIV RT inhibitors have common
properties and cross-resistance exists (51, 61), the exact bind-
ing site for each inhibitor must vary because the degree of
cross-resistance varies, depending on the inhibitor (3, 16, 24,
28, 35). Our data also support this notion. 1506 was completely
inactive against HIV strain N119 (nevirapine resistant), while
it had a modest effect on strain A17 (pyridinone resistant). On
the other hand, the opposite is true with R82150 (TIBO). In
confirmation of previous reports (51, 61, 62), TIBO was com-
pletely inactive against A17, while it had weak activity against
N119. Furthermore, 1506 was active against TIBO-resistant
mutant L100I (46). On the basis of these observations and
other experimental data described below, we postulate that
1506 binds to HIV-1 RT in a fashion similar to that of nevi-
rapine. X-ray crystallography analysis has shown that nevirap-
ine binds to a conserved hydrophobic pocket (amino acids 180
through 190) that is near but not at the substrate binding site
(11, 36, 39). A photoaffinity binding experiment showed that
residues Tyr-181 and Tyr-188 are the nevirapine binding sites
(7). This region has been suggested to be involved in the
‘‘precise positioning of the template-primer relative to the ac-
tive site’’ (33). As described below, our experimental data and
other considerations are consistent with our hypothesis. (i) An
HIV-1 mutant resistant to 1506 had an amino acid change at
the 188th position (Tyr to Leu), and this gave complete resis-
tance to nevirapine and other nonnucleoside inhibitors (4, 62,
FIG. 4. Inhibitory effects of 1506 and other RT inhibitors on wild-type (open
symbols) and mutant HIV-1 (T188L; closed symbols) RTs. Assays were per-
formed with poly(rC) z oligo(dG) as the template-primer in the presence of 1506
(circles), R82150 (TIBO) (rectangles), and foscarnet (triangles). RT activities in
the presence of various concentrations of inhibitor are expressed as percentages
of controls measured without inhibitors.
FIG. 5. Isobologram plots of the inhibition of HIV cytopathic effects on
MT-4 cells by combinations of 1506 and nucleoside RT inhibitors. The combined
effects of 1506 and AZT (a) or ddC (b) on MT-4 cells infected with HIV-1IIIB
were evaluated. The line between values for individual drugs indicates the values
at which additive effects occur. Values below and to the left of this line indicate
synergy.
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72). (ii) 1506 and nevirapine have a common structural feature
of two aromatic rings bridged by an eight- or seven-membered
ring. Like many other nonnucleoside RT inhibitors, nevirapine
has a ketone-containing heterocyclic ring structure (23, 37, 40,
47); 1506 does not. However, the halogen or hydroxy groups of
1506 may yield electronegativity in a way similar to that of the
heterocycle. (iii) The electronegative group of nonnucleoside
inhibitors has been postulated to bind to the Lys at positions
101 through 104 (40, 66). The halogen group of 1506 may also
bind to this region. (iv) Like nevirapine, 1506 inhibits the
TIBO-resistant HIV-1 mutant L100I. This suggests that bound
1506 or nevirapine does not extend to cover the Leu at position
100 and that the binding of TIBO is different from that of 1506
or nevirapine.
The most striking effect of the gomisin J modifications was
the large increase in anti-HIV activity caused by halogenation
of positions 4 and 9. This increase in activity was not accom-
panied by a parallel increase in toxicity. An increase in anti-
HIV activity caused by halogenation has also been reported for
TIBO derivatives (53). The increase in anti-HIV activity for
TIBO may be due to facilitated cellular uptake of halogenated
derivatives, because in vitro RT inhibitory activities remain
unchanged by halogenation (53). On the other hand, the ha-
logenation of gomisin J as well as pyridinone derivatives (24)
results in increased in vitro inhibitory activity for HIV RT. The
introduction of a methyl or ethyl group into positions 4 and 9
increased anti-HIV activity, but cell toxicity also increased.
The introduction of an n-propyl or n-butoxy group to positions
4 and 9 reduced anti-HIV activity dramatically. Furthermore,
the introduction of a methyl or ethyl group into the hydroxy
groups at positions 3 and 10 resulted in a loss of activity,
indicating the importance of these hydroxy groups (data not
shown).
In general, nonnucleoside RT inhibitors are absorbable
through the gastrointestinal tract to maintain a high concen-
tration in serum (13, 47, 53). In accordance with this general
rule, in a preliminary experiment, a single oral administration
of 30 mg of 1506 per kg to individual rats resulted in a 1.8 mM
concentration in serum without apparent toxicity to these an-
imals. Together with the fact that AZT-resistant HIV-1 mu-
tants are susceptible to gomisin J derivatives and that 1506
works synergistically with AZT, these observations suggest that
further studies of gomisin J derivatives are warranted, espe-
cially in light of the recent evidence that HIV actively multi-
plies continuously until the infected individual dies (18, 29).
The emergence of strains resistant to anti-HIV agents does
not necessarily mean that these agents are unuseful, because
some resistant mutations are bound to retard the multiplica-
tion rate of the virus (6). Thus, proper combinations of various
anti-HIV RT and/or anti-HIV PR agents may cause attenuated
forms of the virus and therefore prolong the survival of indi-
viduals. This approach is especially important because of the
recent emergence of HIV strains resistant to various PR in-
hibitors (8).
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